background section
Procagen
- CompanyIntroduction
- Company Introduction
- Our Vision
- History
- Our team
- Core Value
- Locations
- Service
- Technology(R&D)
- Technology (R&D)
- PRS
- AI-based/healthcare
- Intellectual property/Certification
- PRcenter
- PR center
- Notice
- News
- Video
- E-brochure
- R&D network
- CustomerService
R&D
We are committed to develop AI-based prediction and diagnosis algorithms of urologic tumors and male diseases
PR CENTER
SERVICE
Prediction and diagnosis services for Urologic tumors and male diseases
Quick
PRS
Prostate cancer
- Account for 10% of total prostate cancer
- Rare genetic variants
BRCA1, BRCA2, ETC - common genetic variants
- Total number of SNPs
- Cancer-related rare genetic changes are very powerful, but account for less than 10% of cancer. Although each effect of common genetic variants is minimal, combined forces can cause cancer
- Polygenic Risk Score
- Procagen considers the importance of each of the numerous genetic variants and presents the risk of cancer as a score.
AI-based·healthcare
visual image
AI technology is no longer an option, it's a must
- Procagen is applying AI technologies into our services in order to efficiently manage and analyze out big data
- For this. We are discovering and fostering AI researchers, and promoting product innocation through AI technology in various channels such as consulting with AI experts and collaborating with AI companies. We are developing an AI SW as a medical device that calculates the current probability of having prostate cancer and this AI SW can be used for prostate biopsy decisio
